drugset / Trial / NCT05392179
A Study in Subjects With Retinitis Pigmentosa
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Timeline
- Start
- 2022-07-14
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 400 ug | Intravitreal |